Harper, Hooper Exit As Amgen Revenues Rise
Executive Summary
Amgen revealed better-than-expected second quarter earnings July 26 and said its R&D and commercial heads Sean Harper and Anthony Hooper are retiring. Harper, who's getting involved with start-ups, is being replaced from within by David Reese; Bristol's Murdo Gordon will take over for Hooper.
You may also be interested in...
Amgen Shadow Pricing Of Enbrel Under Scrutiny At US House Hearing
Amgen CEO Bradway told Congress the biggest driver of list pricing for Enbrel has been the need to match the price of AbbVie's Humira to secure formulary access.
Amgen Shadow Pricing Of Enbrel Under Scrutiny At US House Hearing
Amgen CEO Bradway told Congress the biggest driver of list pricing for Enbrel has been the need to match the price of AbbVie's Humira to secure formulary access.
Amgen's Aimovig Riding High With Strong Prescriber, Payer Acceptance
New commercial head Murdo Gordon described Aimovig as one of the best launches he's ever seen and said growth should continue – though moderate – based on prescriber experience and rapid transitions from free drug to reimbursed prescriptions.